Trials / Completed
CompletedNCT00052065
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (planned)
- Sponsor
- Telik · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLK286 |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2006-03-01
- Completion
- 2006-03-01
- First posted
- 2003-01-23
- Last updated
- 2011-07-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00052065. Inclusion in this directory is not an endorsement.